Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) c ohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg , and 40 mg). - ASC30 oral once-daily tablet also...

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30...

menu
menu